ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2447

Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs

Enrique R Soriano1, Hugo Madariaga2, Oswaldo Castañeda3, Gustavo Citera4, Emilce E Schneeberger4, Mario H Cardiel5, Thijs Hendrikx6, Daniela Graham7, Harry Shi6 and Dario Ponce de Leon8, 1Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Clínica del Sur, Arequipa, Peru, 3Clínica Anglo Americana, Lima, Peru, 4Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 5Centro de Investigación Clínica de Morelia, Morelia, Mexico, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Lima, Peru

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: liver disease, psoriasis, Psoriatic arthritis, rheumatoid arthritis (RA) and tofacitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Non-alcoholic fatty liver disease, characterized by hepatic steatosis (HS), is a very common form of chronic liver disease in many countries. Limited data are available on liver enzyme elevation in patients (pts) with HS who are receiving medications for inflammatory conditions, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO). Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and PsA, and has also been studied in PsO. The objective of this study was to describe baseline characteristics and liver enzyme abnormalities in pts from the tofacitinib RA, PsA, and PsO clinical programs with/without HS at baseline.

Methods: Pts randomized to the tofacitinib (5 or 10 mg twice daily; doses pooled) and placebo arms of 25 studies in the RA, PsA, and PsO programs were included in this pooled post hoc analysis. Most studies allowed or mandated concomitant treatment with disease-modifying antirheumatic drugs. HS was determined by the investigator and captured per the Medical Dictionary for Regulatory Activities term at baseline. Baseline characteristics, incidence of elevated total bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >1x and >3x the upper limit of normal (ULN) up to Month (M) 3, and change from baseline in C-reactive protein (CRP) at M3 – all by HS at baseline – are reported.

Results: A total of 10,212 pts were included in the analysis. The prevalence of HS was 1.6% across indications (RA: 87/6,729 [1.3%]; PsA: 27/710 [3.8%]; PsO: 45/2,773 [1.6%]). Baseline characteristics were generally similar in pts with or without HS (Table). However, baseline obesity, diabetes, triglycerides, and liver enzymes were numerically higher, and CRP was numerically lower, in pts with HS than in those without HS (Table). In both tofacitinib- and placebo-treated pts, incidence of elevated total bilirubin, AST and ALT >1x ULN up to M3 was higher in pts with HS than in those without HS, across indications (Table). Incidence of elevated total bilirubin, AST and ALT >3x ULN up to M3 was low across indications, irrespective of HS (Table). Among tofacitinib-treated pts, CRP was reduced at M3 in pts with or without HS, but to a lesser extent in those with HS, across indications. Among placebo-treated pts, changes in CRP were small, irrespective of HS (Table).

Conclusion: In this exploratory analysis, prevalence of HS at baseline was 1.6% across the tofacitinib RA, PsA, and PsO programs. After up to 3 months of tofacitinib treatment, incidence of mildly elevated liver enzymes was higher in pts with HS than in those without HS. Incidence of severely elevated liver enzymes was low overall, and similar in pts with or without HS. Further studies are needed to evaluate the effects of tofacitinib on CRP and liver enzymes, and the potential impact on clinical response, in pts with RA, PsA, or PsO who have comorbid HS.



Disclosure: E. R. Soriano, AbbVie, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer Inc, Roche, UCB, 2,AbbVie, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, 5,AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sandoz, UCB, 8; H. Madariaga, None; O. Castañeda, None; G. Citera, Novartis, Pfizer Inc, 2,AbbVie, Bristol-Myers Squibb, Eli Lilly, Genzyme, Novartis, Pfizer Inc, Roche, 5; E. E. Schneeberger, None; M. H. Cardiel, Gilead, Pfizer Inc, Roche, 2,Eli Lilly, Pfizer Inc, 5,Eli Lilly, Pfizer Inc, 8; T. Hendrikx, Pfizer Inc, 1,Pfizer Inc, 3; D. Graham, Pfizer Inc, 1,Pfizer Inc, 3; H. Shi, Pfizer Inc, 1,Pfizer Inc, 3; D. Ponce de Leon, Pfizer Inc, 1,Pfizer Inc, 3.

To cite this abstract in AMA style:

Soriano ER, Madariaga H, Castañeda O, Citera G, Schneeberger EE, Cardiel MH, Hendrikx T, Graham D, Shi H, Ponce de Leon D. Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/liver-enzyme-abnormalities-after-tofacitinib-treatment-in-patients-with-hepatic-steatosis-from-the-rheumatoid-arthritis-psoriatic-arthritis-and-psoriasis-clinical-programs/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/liver-enzyme-abnormalities-after-tofacitinib-treatment-in-patients-with-hepatic-steatosis-from-the-rheumatoid-arthritis-psoriatic-arthritis-and-psoriasis-clinical-programs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences